T he complexity of blood pressure regulatory mechanisms suggests that combined use of antihypertensive drugs with different pharmacological actions to achieve synergism is a rational approach to obtain optimal control of hypertension.
T he complexity of blood pressure regulatory mechanisms suggests that combined use of antihypertensive drugs with different pharmacological actions to achieve synergism is a rational approach to obtain optimal control of hypertension. 1 Recent hypertension guidelines also recommend initiating antihypertensive therapy with 2 drugs if blood pressure is >20 mm Hg above systolic goal or >10 mm Hg above diastolic goal. 2, 3 In most countries, more than half of treated patients with hypertension are indeed on ≥2 drugs. 2, 4 Moreover, patients with hypertension are often associated with other cardiovascular risk factors and comorbidities, which may further increase the pill burden. Therefore, polypharmacy and resultant noncompliance are both frequently encountered problems in the management of hypertension. 5 To simplify complex medical regimens and improve adherence, the use of combinations of ≥2 antihypertensive drugs at fixed doses in a single tablet, commonly called fixed-dose combinations or single-pill combinations (SPCs), has been advocated in several hypertension guidelines. 2, 3, 6, 7 In a recent meta-analysis of studies comparing the administration of antihypertensive SPCs with their corresponding free-drug combinations, the compliance rate was improved by 21% in patients receiving SPCs. 8 However, most evidences showing that SPCs were associated with improved adherence are from cohort studies with parallel group comparisons and without adjustments for comorbidities and concomitant medications. The only relevant randomized crossover studies were of small size and conducted ≈3 decades ago. 9, 10 In other words, there are no reported studies assessing the effects of SPCs on adherence in real-world patients with hypertension switched from free-drug combinations to SPCs. Given that SPCs have also been accused of reduced flexibility in dosing and possible increased adverse effects, it is of importance to examine whether the common practice of switching from free-drug combinations to SPCs does invariably achieve better adherence in diverse patients with hypertension.
The computerized claims database of the National Health Insurance (NHI) in Taiwan provides us a unique opportunity to carry out such a study. In this study, we aimed to assess (1) the effect of switching from antihypertensive free-drug combinations to the corresponding SPCs on overall adherence and adherence in subgroups stratified by their adherence with free-drug combinations and (2) demographic and clinical factors associated with adherence changes to refine the strategic use of SPCs in the management of hypertension. A 1-year mirror-image design was used to eliminate the influences of uncontrollable confounding factors. 11 We further included 2 reference groups (treated with identical free combinations and SPCs, respectively) with similar inclusion criteria to account for the phenomenon of regression to the mean.
Methods Data Source
This study is a retrospective cohort analysis using a 1 000 000-person representative random sample from the computerized Taiwan NHI reimbursement database between January 2001 and December 2007. 12 The NHI program, a mandatory universal healthcare system enrolling ≈99% of the 23 million people in Taiwan, was instituted in March 1995. The NHI database includes ambulatory care claims, inpatient claims, and pharmacy claims containing information on refillable prescriptions, the filling dates, and days covered by the prescriptions. All data were encrypted to maintain patients' confidentiality.
The target population includes patients with hypertension who were switched from free-drug combinations to the corresponding SPCs of the same compounds. The present study used a mirror-image design to compare the adherence of either free-drug combinations or SPCs in an equal follow-up period. The 1-year period was determined to balance the intention to obtain information about long-term adherence and the wish for a reasonably large number of patients eligible for the full mirror-image period. To be eligible for enrollment, patients should fulfill all of the following criteria: (1) having a diagnosis of hypertension, based on the International Classification of Diseases-9 diagnosis codes 401 to 405, ≥12 months before the index date (the date on which free-drug combination switched to the corresponding SPC); (2) having ≥2 prescriptions of both an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) and a thiazide-type diuretic with 1 prescribed 12 months before the index date and the other within 1 month before the index date to assure the long-term necessity of the designated free-drug combination to control blood pressure; (3) having an initial prescription of an SPC composed of the same compounds prescribed in the preindex period; and (4) having ≥1 prescription of the same SPC 12 months after the index date. To examine the generalizability of current findings, we further enrolled an expanded target population by adjusting the 12 months requirement set for the above-mentioned criteria 2 and 4 to 6 months for sensitivity analyses.
To adjust for the possible influences of regression to the mean, we selected 2 reference groups consisting of patients with hypertension treated with identical free combinations (reference group 1) or SPCs (reference group 2) composed of both an ACE inhibitor or ARB and a thiazide-type diuretic for ≥24 months. The inclusion criteria of both reference groups are similar to that of the target population and briefly described below: (1) having prescriptions of identical free combinations or SPCs consisting of both an ACE inhibitor or ARB and a thiazide-type diuretic on the index date and ≥12 months before and after the index date; (2) having an initial prescription of the designated free combinations or SPCs 18 months before the index date to avoid the influence of early drug adjustment; (3) having never been treated with SPCs (for reference group 1); and (4) not fulfilling the inclusion criteria of the target population (for reference group 2).
Adherence with free-drug combinations or SPCs was measured by medication possession ratio (MPR), defined as total number of days covered by filled prescriptions of free-drug combinations or SPCs divided by 365 (total days of observation of either treatment modality). Patients were then stratified into 3 subgroups according to their preindex MPRs: low adherence (MPR <0.5), intermediate adherence (MPR ≥0.5 and <0.8), and high adherence (MPR ≥0.8).
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Demographic and clinical characteristics of each patient on the index date were obtained from the NHI database, including age, sex, types of clinical facilities, month of index date, comorbid diseases, number of other antihypertensive drugs, and number of other concomitant medications. Comorbid diseases include hyperlipidemia, diabetes mellitus, coronary heart disease, previous myocardial infarction, congestive heart failure, stroke, dementia, and chronic kidney disease. According to the presence or absence of comorbid diseases, the Charlson comorbidity index was computed. 16 
Statistical Analyses
Categorical variables were summarized as counts or percentages and compared using the Pearson χ 2 test. Continuous variables were presented as mean±SD and compared using the 1-way ANOVA, followed by post hoc analyses using the Bonferroni test. 
Results
From 2001 to 2007, a total of 270 018 patients with hypertension treated with antihypertensive medications were identified in the 1 000 000-person NHI Research Database. Among them, 23 581 (8.7%) patients had been treated with SPCs composed of an ACE inhibitor or ARB and a thiazide-type diuretic. Of all these SPC-treated patients, 4131 (18%) patients were switched from free-drug combinations of the same components of the corresponding SPCs (an ACE inhibitor or ARB and a thiazide-type diuretic), whereas for the remaining 19 450 patients, SPCs were prescribed either as an initial antihypertensive drug or as an add-on therapy. To ensure equal comparability and sustained (>1 year) necessity of both free-drug combinations and SPCs, we chose patients treated with free-drug combinations and the corresponding SPCs for ≥1 year before and after switching, respectively (the 1-year mirror-image design). Finally, 896 patients with hypertension fulfilling the inclusion criteria were enrolled as the target population (study group; Figure 1 ).
The characteristics of the 896 patients on the index date are shown in Table 1 . Mean age of the subjects was 65.8 years, and 44% were ≥70 years. Overall, 77% of patients were treated with additional antihypertensive drugs except the SPC, whereas 85% of patients received ≥1 other drug (not limited to antihypertensive drugs) besides the SPC.
Among the 246 437 patients with hypertension who had never been treated with SPCs, 2577 patients treated with identical free combinations of both an ACE inhibitor or ARB and a thiazide-type diuretic on the index date and ≥12 months before and after the index date were included as the first reference group, whereas a total of 831 patients treated with identical SPCs were included as the second reference group (Figure 1) . Compared with the study population, patients in both reference groups were younger, less often female, more often managed at primary care clinics, and had fewer other antihypertensive and concomitant drugs and lower Charlson index (Table 2) .
For the 896 patients in the study group, the mean MPR was 42% in the first 12-month free-combination (preindex) period. Only 19% of patients achieved high adherence (MPR ≥0.8).
Compared with patients with low adherence (MPR <0.5), patients achieving high adherence were older, more often female, and less frequently managed at primary care clinics (Table 1 ). There was no difference in the average Charlson index, as well as the mean number of other antihypertensive or concomitant drugs prescribed among patients with different levels of preindex adherence. In the 12-month postindex period, the mean MPR was 69%, significantly higher than that in the preindex period. Approximately one half (49%) of patients in the study group achieved high adherence to SPCs. The difference in MPR in the whole study group (absolute difference, 27%; 95% confidence interval [CI], 24%-30%; P<0.001; relative difference, 75%; 95% CI, 58%-100%; P<0.001) was significantly greater than that in the 2 reference groups even after adjustments for age, sex, preindex MPR, number of concomitant antihypertensive drugs, and Charlson index (Table 3) .
To examine whether the difference in MPR was consistent in patients with different preindex adherence levels, we categorized patients according to their preindex MPR (high, ≥0.8; intermediate, ≥0.5 and <0.8; low, <0.5) and compared the preand postindex MPRs separately ( Table 3) . As a result, there were significant differences between the pre-and postindex MPRs across the 3 subgroups in the study group. However, the changes in MPR were bidirectional. In patients with low or intermediate preindex adherence (n=729) in the study group, switching to SPCs achieved significant improvements in MPR (absolute difference, 36%; 95% CI, 33%-39%; P<0.001), whereas in patients with high preindex adherence (n=167), switching to SPCs unexpectedly resulted in a significant reduction in MPR (absolute difference, −13%; 95% CI, −17% to −9%; P<0.001). The negative effect on the postindex MPR in patients with high preindex adherence remained significant even after excluding patients with the preindex MPR of 1.0 (n=100; difference, −10%; 95% CI, −16% to −5%; P<0.001). Albeit numerically smaller than that in the study group, it is noteworthy that the bidirectional response was also observed in both reference groups, indicative of the phenomenon of regression to the mean. After accounting for the MPR differences in the reference groups and adjusting for possible confounding factors including age, sex, preindex MPR, number of other antihypertensive drugs, and Charlson index, switching to SPCs remained associated with a significant reduction in MPR in patients with high preindex adherence levels, whereas for patients with low preindex adherence levels, switching to SPCs consistently resulted in a significant increase in MPR. However, the increase in MPR was no longer significant in patients with intermediate preindex adherence levels ( Table 3) .
We then performed linear regression analyses to further assess the relationships between preindex MPR and MPR difference in the study group and both reference groups. An inverse relationship between preindex MPR and MPR difference was demonstrated in all groups (Figure 2) . However, the slope of regression equation was greatest in the study group, together with the largest r value (r=0.631; P<0.001). Likewise, the scatter plots showed individual values of MPR difference tended to cluster around the zero line in both reference groups ( Figure 2B and 2C) compared with those in the study group (Figure 2A ). According to the regression equation of the study group [MPR difference (%)=59-0.77×(preindex MPR in %)], the cutoff point of preindex MPR to differentiate positive and negative effects of switching to SPCs on MPR difference rests on 77%, which is close to the widely accepted cutoff definition for high adherence (80%). The corresponding cutoff points in patients treated with free combinations (reference group 1) and with SPCs (reference group 2) were 63% and 84%, respectively.
Besides the preindex MPR, several patient characteristics influenced the adherence changes incurred by switching to SPCs. After adjustment for age, sex, and the preindex MPR, MPR difference was inversely related to the number of other antihypertensive and concomitant drugs, Charlson index, congestive heart failure, and chronic kidney disease ( Table 4 ). The MPR differences were 3.6 and 1.3 percentage points lower for every increase of the number of other antihypertensive and concomitant drugs, respectively. After controlling for all possible confounding factors, the inverse relationships between MPR differences and the preindex MPR, the number of other antihypertensive drugs, and congestive heart failure remained statistically significant ( Table 5 ). The regression equation obtained from the multivariate analysis was MPR difference (%)=65.6-0.77×(preindex MPR in %)-11.2×(congestive heart failure; %)-3.2×(number of other antihypertensive drugs). According to this equation, for patients with congestive heart failure and 1 other antihypertensive drug, the cutoff point of preindex MPR to differentiate positive and negative effects of SPC on MPR differences rests on 60%.
By categorizing patients according to the number of other antihypertensive drugs, the benefits of switching to SPCs were significantly greater in patients treated with <3 other antihypertensive drugs compared with those treated with ≥3 other antihypertensive drugs (Figure 3 ). In contrast, in both reference groups, the MPR difference was significantly smaller in patients treated with <3 other antihypertensive drugs compared with those treated with ≥3 other antihypertensive drugs ( Figures  S1 and S2 in the online-only Data Supplement). This finding is possibly because of the lower preindex MPRs in patients treated with ≥3 other antihypertensive drugs and reflects the phenomenon of regression to the mean in both reference groups. It also substantiates the contrast finding observed in the study group.
All these results remained similar when the sensitivity analyses were performed in the expanded study group (n=1139 ;  Table S1 and Figure S3 ).
Discussion
In this study, we have made 4 major observations. First, by analyzing this large nationwide representative database, we showed that the adherence to antihypertensive drugs was far from ideal in patients with hypertension treated with ≥2 antihypertensive drugs for ≥1 year. The average prescription refill frequency, 42% for the target population and 55% for all relevant patients enrolled, is consistent with most previous studies worldwide. [17] [18] [19] Second, we demonstrated that, overall, switching from free combinations of 2 antihypertensive drugs to the corresponding SPCs could result in significant improvement in medication adherence in the real world, even after adjustments for the phenomenon of regression to the mean. The magnitude of improvement in adjusted MPR difference observed in the study group (relative and absolute differences in MPR, 50%-61% and 21-26 percentage points, respectively) is greater than that reported in most previous studies, irrespective of the strategies used for improving adherence. [20] [21] [22] [23] Third, despite of the overall improvement in medication adherence, we for the first time demonstrated that the responses to switching to SPCs were bidirectional rather than uniform. For patients with suboptimal adherence to free combinations, switching to SPCs could achieve significant improvement in medication adherence, whereas for patients already having good adherence (MPR ≥0.8) to free combinations, switching to SPCs could make adherence worse. Fourth, contrary to general belief, 24 we demonstrated that the benefit of SPCs in improving adherence was inversely related to the number of concomitant antihypertensive medications. This finding further supports early use of SPCs in the management of hypertension. The mirror-image (crossover) nature of this cohort study further substantiates the validity of our findings by excluding influences of patient-specific confounding factors.
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In Taiwan, the full prescription coverage system renders no copayments for antihypertensive drugs. However, the average MPR in patients treated with ≥2 antihypertensive drugs for ≥1 year is only ≈50%. This finding is in keeping with the Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) trial, 20 in which the elimination of copayments for drugs prescribed after myocardial infarction, with a median follow-up of 394 days, increased overall adherence from 39% to 44% only. These results suggest that elimination of financial hurdles alone is not enough in improving adherence.
In contrast to the modest effect of copayment elimination, the use of antihypertensive SPCs, compared with prescriptions of equivalent free combinations, has been shown to increase adherence from 7 to 22 percentage points in different studies. 8, 25, 26 In this study, the magnitude of improvement in unadjusted adherence (27 percentage points) is the greatest among all relevant studies. There are several possible explanations for this finding. First, because the improvement in adherence associated with the use of SPCs is inversely related to the MPR associated with equivalent free combinations, the marked improvement observed may be because of the relatively low baseline MPR, 42%. In fact, the MPR of free combinations herein is also the lowest among all relevant studies. 8, 25 This is further supported by the smaller magnitude of improvement in MPR observed in the expanded study group that had a higher preindex MPR (Table S1 ). Second, because we included only patients treated with SPCs for ≥12 months, we inevitably excluded those noncompliant patients who permanently discontinued their SPCs before 12 months. This selection bias may make us overestimate the effect of SPCs. However, the same inclusion criterion (treatment for ≥12 months) was also applied to the free combinations. Hence, the real MPR associated with free combinations may be even lower than the current level. Given the inverse relationship between baseline MPR and the improvement by SPCs, the effect of SPCs may be therefore offset. The 2 opposing effects may intriguingly make the observed magnitude of improvement close to clinical reality.
One novel finding of this study is that the effect of SPCs on adherence is bidirectional, despite in general the use of SPCs is associated with marked improvement in adherence. This finding is essentially in line with the inverse relationship between baseline MPR and the increase of adherence with the use of SPCs. Although this finding is in keeping with the phenomenon of regression to the mean and there is indeed significant regression to the mean effect in both reference groups, we showed that the inverse relationship between baseline MPR and MPR difference remained statistically significant after adjustment for this phenomenon. It is of interest that the watershed of baseline MPR separating the positive and negative effects on adherence rests on ≈80%, the most adopted, but not so evidence-based, standard for good adherence. 14, 15 Although there are no previous nonrandomized or retrospective cohort studies including only adequate adherers, it is self-explanatory that the effect of SPCs on adherence is not evident in adequate adherers. One recently published randomized, controlled trial, in which the average adherence was 98%, showed that treatment with antihypertensive SPCs resulted in a similar adherence in contrast to equivalent free combinations during the 6-month period. 27 However, switching free-combination antihypertensive drugs to the equivalent SPCs could worsen medication adherence in adequate adherers is demonstrated for the first time in this study. The possible explanations include, first, patients who regularly refilled their prescriptions of 2 free-combined antihypertensive drugs may not take both of their antihypertensive medications as the doses prescribed and at the same time. Therefore, although these patients were switched to the equivalent SPCs, their blood pressures may be lowered too much. Patients may therefore become nonadherent or reduce the doses of SPCs by themselves. Second, the reduced adherence with SPCs may reflect the lack of flexibility with SPCs in dose adjustments in Taiwan, where the availability of different doses of SPCs is limited. For most patients with high adherence to 2 free-combined antihypertensive drugs, if they indeed adjust the doses of their antihypertensive drugs, they theoretically adjust only 1 agent rather than both agents. The reason for this assumption is because if they adjust the doses of both agents, they should have both drugs in excess and do not need to refill their prescriptions that regularly to make their MPR ≥0.8. However, when these high-adherent patients were switched to the equivalent SPCs, they can only adjust the single SPC. As a consequence, they will have surplus of their SPCs and do no need to refill their prescriptions in such a timely manner. Hence, the corresponding MPR dropped. Despite the clinical significance of this intriguing finding is still not certain, it seems prudent to maintain free-combined antihypertensive drugs for patients with high medication adherence, given the lack of evidence that SPCs do improve medication adherence in this subset of patients with hypertension, particularly in countries where the choice of different doses of SPCs is limited.
Another provocative finding of this study is that the improvement of adherence with the use of SPCs is inversely related to the number of concomitant antihypertensive drugs. It is commonly believed that complexity of treatment and increased pill burden are often associated with inadequate adherence. 14, 28 Because the improvement of adherence with SPCs is inversely related to baseline MPR, it is assumed that the benefit of SPCs should be more evident in patients with a higher pill burden. However, some studies showed that increased number of medications may not result in decreased adherence and sometimes is even associated with better adherence. 13, 29, 30 It is plausible that patients treated with more medications usually have more severe clinical conditions and are more willing to follow the therapeutic regimen. In this study, we also found that the MPR was not decreased with increased number of concurrent medications in the study group. Moreover, we demonstrated for the first time that the benefit of switching from free combinations to equivalent SPCs is primarily observed in patients with fewer (<3) concomitant antihypertensive drugs rather than in those with a higher pill burden. In fact, the psychological effect of pill burden reduction by switching to SPCs (minus 1 tablet) should be greater in patients with fewer medications. Hence, it is conceivable that the benefit of SPCs is more evident in patients treated with fewer medications rather than in those treated with more medications as commonly believed. This finding further corroborates the recent observations that early or even initial use of SPCs could improve hypertension control and cardiovascular outcomes, of which adherence improvement with SPC use is probably one of the essential mechanisms.
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Limitations
There are some limitations in this study. First, prescription refill information was obtained from the electronic reimbursement claim database, and it is difficult to verify whether these patients truly consumed their medications. However, because of the mirror-image design, the same limitation was imposed on both free combination and SPC treatment periods, and its influence may thus be neutralized. Second, although it is assumed that physicians should adopt the same principle in these patients no matter what antihypertensive medications were prescribed, we cannot exclude the possibility that physicians might have emphasized the importance of adherence while switching from free combinations to equivalent SPCs and thus affected outcomes. Nevertheless, we demonstrated that the adherence changes associated with SPC use were not uniform, thus refuting the importance of this concern. Third, because we included only patients treated with ≥2 antihypertensive drugs, it is not possible to determine whether results of this study could be generalized to all patients with hypertension. Fourth, although we included 2 reference groups to account for the influence of regression to the mean, it is still possible that the negative effect of switching to the corresponding SPCs in free-combination high adherers could simply be a reflection of the regression to the mean phenomenon. Further studies to validate this finding are definitely needed. Last, the available electronic database did not contain information of blood pressure measurements. We thus could not assess the effects of different therapeutic regimens on blood pressures and whether achieved blood pressures could influence adherences with different regimens, particularly for patients with a high preindex MPR.
Perspectives
A plethora of studies show that significant gaps between evidence and its implementation are global problems, particularly in chronic diseases like hypertension. 33 These gaps become even greater because the adherence declines markedly over time. Efforts to reduce these gaps will confer greater population benefits than most novel treatments and should be a priority for tackling the global burden of hypertension. By analyzing the nationwide representative database, we not only demonstrated an unacceptably low adherence (1-year MPR ≈40%) to 2 antihypertensive drugs given separately in patients with hypertension treated with ≥2 antihypertensive drugs but also showed a significant 75% relative increase in 1-year MPR with the strategy of switching to the corresponding SPCs. More importantly, despite the seemingly magic bullet effect of SPCs on improving medication adherence, this strategy is not effective and may even worsen adherence in patients with hypertension adequately adhering to their original free-combined antihypertensive regimens. However, switching from free-combined antihypertensive drugs to their corresponding SPCs is more effective in improving adherence in patients with hypertension treated with fewer antihypertensive drugs (ie, less pill burden). These findings suggest early or even initial use of SPCs to curtail the gaps between evidence and sustained implementation of antihypertensive therapy. Whether this strategy will improve patient outcomes merits further investigations.
